Investor Presentaiton

Research and Development Ulotaront: Development Progress and Future Plans (Co-Development with Otsuka Pharmaceutical) Schizophrenia: Clinical program lead: Sunovion/Sumitomo Pharma Phase 3 DIAMOND clinical study program on-track Results from the efficacy studies (DIAMOND 1 and DIAMOND 2 studies) anticipated in H1 FY2023 NDA submission to the U.S. FDA is anticipated in FY2023 Adjunctive treatment of major depressive disorder (aMDD): Clinical program lead: Otsuka Pharmaceutical First patient randomized in November 2022 Phase 2/3 study is ongoing Generalized Anxiety Disorder (GAD): Clinical program lead: Sunovion/Sumitomo Pharma First patient randomized in April 2023 Phase 2/3 study is ongoing Sumitomo Pharma © Sumitomo Pharma Co., Ltd. All Rights Reserved. 18

View entire presentation